Home › Non-Small Cell Lung Cancer › Minnesota › Rochester
Non-Small Cell Lung Cancer clinical trials in Rochester, MN
37 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Rochester (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #68, Rochester
Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
RecruitingPhase 2
- Mayo Clinic in Rochester, Rochester
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 1/2
- Research Site, Rochester
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
RecruitingPhase 1/2
- Mayo Clinic-Rochester /ID# 274512, Rochester
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RecruitingPhase 3
- Mayo Clinic - Rochester ( Site 0073), Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecruitingObservational study
- Mayo Clinic Rochester, Rochester
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Mayo Clinic Rochester, Rochester
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Mayo Clinic, Rochester
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
RecruitingPhase 3
- Mayo Clinic - Rochester ( Site 0148), Rochester
Pan-tumor MRD Study
RecruitingObservational study
- Mayo Clinic, Rochester
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
RecruitingPhase 2
- Mayo Clinic, Rochester
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
RecruitingPhase 3
- Research Site, Rochester
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
RecruitingPhase 3
- Mayo Clinic, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RecruitingObservational study
- Mayo Clinic (Rochester), Rochester
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Mayo Clinic, Rochester
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RecruitingPhase 1
- Mayo Rochester, Rochester
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RecruitingPhase 3
- Research Site, Rochester
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
RecruitingPhase 1
- Mayo Clinic, Rochester
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
RecruitingPhase 1
- Mayo Clinic, Rochester
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
RecruitingPhase 1
- Mayo Clinic - Rochester, Rochester
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
RecruitingPhase 1/2
- Mayo Clinic-Rochester, Rochester
A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
RecruitingHealthy volunteers welcome
- Mayo Clinic in Rochester, Rochester
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
RecruitingPhase 3
- Mayo Clinic in Rochester, Rochester
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
RecruitingPhase 1/2
- Mayo Clinic Hospital - Rochester, MN, Rochester
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RecruitingPhase 1
- Mayo Clinic Rochester, Rochester
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
RecruitingPhase 1
- Mayo Clinic Cancer Center, Rochester
- Mayo Clinic, Rochester
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
RecruitingPhase 3
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- Mayo Clinic Rochester, Rochester
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RecruitingPhase 1
- Mayo Clinic Comprehensive Cancer Center, Rochester
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
RecruitingPhase 3
- Mayo Clinic, Rochester
Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer
RecruitingPhase 2
- Mayo Clinic in Rochester, Rochester
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RecruitingPhase 1/2
- Mayo Clinic Cancer Center, Rochester
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RecruitingObservational study
- Mayo Clinic, Rochester
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
RecruitingObservational study
- Mayo Clinic in Rochester, Rochester
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
RecruitingPhase 2
- Mayo Clinic (Data Collection Only), Rochester
Insomnia in Patients With Metastatic Lung Cancer
RecruitingObservational study
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- Mayo Clinic, Rochester
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY120 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH56 studies
- Washington, DC55 studies
Other studies in Rochester
- Breast Cancer42 studies
- Metastatic Cancer31 studies
- Cancer (all types)30 studies
- Colorectal Cancer29 studies
- Ovarian Cancer29 studies
- Multiple Myeloma24 studies
- Prostate Cancer22 studies
- Heart Failure22 studies
- Pancreatic Cancer22 studies
- Lung Cancer20 studies
- Endometrial Cancer20 studies
- Chronic Lymphocytic Leukemia19 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.